These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 23299465)

  • 1. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
    Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
    Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins.
    Wong H; Chow TW
    J Pharm Sci; 2017 Sep; 106(9):2270-2275. PubMed ID: 28392453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.
    Li L; Gardner I; Dostalek M; Jamei M
    AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of therapeutic monoclonal antibodies.
    Keizer RJ; Huitema AD; Schellens JH; Beijnen JH
    Clin Pharmacokinet; 2010 Aug; 49(8):493-507. PubMed ID: 20608753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacology and therapeutic applications of monoclonal antibodies.
    Castelli MS; McGonigle P; Hornby PJ
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00535. PubMed ID: 31859459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.
    Glassman PM; Balthasar JP
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.
    Edlund H; Melin J; Parra-Guillen ZP; Kloft C
    Clin Pharmacokinet; 2015 Jan; 54(1):35-80. PubMed ID: 25516414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
    Cao Y; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of FcRn binding assays to guide mAb development.
    Datta-Mannan A; Wroblewski VJ
    Drug Metab Dispos; 2014 Nov; 42(11):1867-72. PubMed ID: 25024401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development.
    Mould DR; Green B
    BioDrugs; 2010 Feb; 24(1):23-39. PubMed ID: 20055530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
    Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A guide to rational dosing of monoclonal antibodies.
    Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
    Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.
    Chetty M; Li L; Rose R; Machavaram K; Jamei M; Rostami-Hodjegan A; Gardner I
    Front Immunol; 2014; 5():670. PubMed ID: 25601866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.
    Ternant D; Bejan-Angoulvant T; Passot C; Mulleman D; Paintaud G
    Clin Pharmacokinet; 2015 Nov; 54(11):1107-23. PubMed ID: 26123705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications.
    Ferl GZ; Theil FP; Wong H
    Biopharm Drug Dispos; 2016 Mar; 37(2):75-92. PubMed ID: 26461173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.